Drug Safety, or Overregulation of Reproductive Health?
Scholar calls for FDA to remove stringent restrictions on medication abortion.
Merger Law Is Dante’s Inferno Revisited
The shift by agencies away from the current guidelines on mergers and acquisitions has left firms in limbo.
Creating a Safe Testing Space for High-Risk AI
Scholars argue for the creation of a regulatory safe space to supplement AI regulations.
CFPB Targets Illegal Junk Fees
New CFPB guidance puts banks on notice that unfair business practices may be met with enforcement action.
Fighting Fires Through Resilience Regulation
Scholars identify wildfire resilience solutions for the power sectors in California and Australia.
Jimmy Carter, The Great Deregulator
By pushing for deregulation and adopting other reforms, President Carter left an enduring legacy on the U.S. regulatory system.
New NCAA Rules Leave Foreign Student-Athletes Behind
Scholars argue that foreign student-athletes must now choose between earning money and keeping their immigration status.
FDA, Not a Federal Judge, Should Decide on Abortion Drugs
Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.
Is Your Phone a Medical Device?
Scholar argues that Congress and FDA should treat risky clinical artificial intelligence tools as medical devices.
FDA Advances Program for Real-World Evidence
FDA’s approach to evidence-based decision-making may not be addressed to the right people.
Underrepresented, Overmedicated, and Misdiagnosed
Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.